1. High SVR12 with 8-week and 12-week glecaprevir/pibrentasvir therapy: An integrated analysis of HCV genotype 1-6 patients without cirrhosis
- Author
-
Tami Pilot-Matias, E.J. Gane, Sandra S. Lovell, Simone I. Strasser, Jean-François Dufour, Federico J. Mensa, Christophe Hézode, Zhenzhen Zhang, David Mutimer, Stanislas Pol, Massimo Puoti, Rui Tato Marinho, Samuel S.S. Lee, Christophe Moreno, Graham R. Foster, Stanley Wang, Stuart C. Gordon, Ting-Tsung Chang, Paul J. Thuluvath, Puoti, M, Foster, G, Wang, S, Mutimer, D, Gane, E, Moreno, C, Chang, T, Lee, S, Marinho, R, Dufour, J, Pol, S, Hezode, C, Gordon, S, Strasser, S, Thuluvath, P, Zhang, Z, Lovell, S, Pilot-Matias, T, and Mensa, F
- Subjects
Cyclopropanes ,Male ,Aminoisobutyric Acids ,Pyrrolidines ,Time Factors ,Cirrhosis ,Sustained Virologic Response ,Sofosbuvir ,Hepacivirus ,Direct-acting antiviral ,Short duration ,Gastroenterology ,chemistry.chemical_compound ,0302 clinical medicine ,600 Technology ,Gastro-entérologie ,030212 general & internal medicine ,610 Medicine & health ,Sulfonamides ,education.field_of_study ,Hepatitis C ,Middle Aged ,Pibrentasvir ,Treatment Outcome ,Female ,030211 gastroenterology & hepatology ,medicine.drug ,Adult ,medicine.medical_specialty ,Genotype ,Proline ,Lactams, Macrocyclic ,Population ,Pangenotypic ,Antiviral Agents ,03 medical and health sciences ,Leucine ,Quinoxalines ,Internal medicine ,medicine ,Humans ,education ,Aged ,Hepatology ,business.industry ,Ribavirin ,Glecaprevir ,Hepatitis C, Chronic ,medicine.disease ,Regimen ,chemistry ,Benzimidazoles ,business - Abstract
Background & Aims: Glecaprevir plus pibrentasvir (G/P) is a pangenotypic, once-daily, ribavirin-free direct-acting antiviral (DAA) treatment for hepatitis C virus (HCV) infection. In nine phase II or III clinical trials, G/P therapy achieved rates of sustained virologic response 12 weeks after treatment (SVR12) of 93–100% across all six major HCV genotypes (GTs). An integrated efficacy analysis of 8- and 12-week G/P therapy in patients without cirrhosis with HCV GT 1–6 infection was performed. Methods: Data were pooled from nine phase II and III trials including patients with chronic HCV GT 1–6 infection without cirrhosis who received G/P (300 mg/120 mg) for either 8 or 12 weeks. Patients were treatment naïve or treatment experienced with peginterferon, ribavirin, and/or sofosbuvir; all patients infected with HCV GT 3 were treatment naïve. Efficacy was evaluated as the SVR12 rate. Results: The analysis included 2,041 patients without cirrhosis. In the intent-to-treat population, 943/965 patients (98%) achieved SVR12 when treated for eight weeks, and 1,060/1,076 patients (99%) achieved SVR12 when treated for 12 weeks; the difference in rates was not significant (p = 0.2). A subgroup analysis demonstrated SVR12 rates > 95% across baseline factors traditionally associated with lower efficacy. G/P was well tolerated, with one DAA-related serious adverse event (, SCOPUS: ar.j, info:eu-repo/semantics/published
- Published
- 2018
- Full Text
- View/download PDF